公司問答 | 萬潤股份:公司積極佈局熱塑性聚酰亞胺材料領域,主要開發的PTP-01產品已實現中試產出產品的供應
格隆匯5月25日丨有投資者在互動平台向萬潤股份提問:公司在機構調研時説,PTP-01產品已經實現了中試供貨,請問在蓬萊新產線投產以前,是不是也能大規模量產?萬潤股份迴應:公司積極佈局熱塑性聚酰亞胺材料領域,主要開發的PTP-01產品已實現中試產出產品的供應,PTP-01產品的量產計劃包括在中節能萬潤(蓬萊)新材料一期建設項目中,已經於2022年通過了PTP-01國內首次使用化工工藝安全可靠性論證評審等。目前該項目正在積極推進中,力爭儘早投入使用實現量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.